Candidiases, infections caused by germination forms of the Candida fungus, represent a heterogeneous group of diseases from systemic infection, through mucocutaneous form, to vulvovaginal form. Although caused by one organism, each form is controlled by distinct host immune mechanisms. Phagocytosis by polymorphonuclears and macrophages is generally accepted as the host immune mechanism for Candida elimination. Phagocytes require proinflammatory cytokine stimulation which could be harmful and must be regulated during the course of infection by the activity of CD8+ and CD4+ T cells. In the vaginal tissue the phagocytes are inefficient and inflammation is generally an unwanted reaction because it could damage mucosal tissue and break the tolerance to common vagina antigens including the otherwise saprophyting Candida yeast. Recurrent form of vulvovaginal candidiasis is probably associated with breaking of such tolerance. Beside the phagocytosis, specific antibodies, complement, and mucosal epithelial cell comprise Candida eliminating immune mechanisms. They are regulated by CD4+ and CD8+ T cells which produce cytokines IL-12, IFN-gamma, IL-10, TGF-beta, etc. as the response to signals from dendritic cells specialized to sense actual Candida morphotypes. During the course of Candida infection proinflammatory signals (if initially necessary) are replaced successively by antiinflammatory signals. This balance is absolutely distinct during each candidiasis form and it is crucial to describe and understand the basic principles before designing new therapeutic and/or preventive approaches.

Department of Immunology Medical Faculty Palacký University 772 00 Olomouc Czechia

Zobrazit více v PubMed

Folia Microbiol (Praha). 2006;51(1):3-20 PubMed

J Med Vet Mycol. 1997 May-Jun;35(3):197-203 PubMed

J Infect Dis. 2000 Nov;182(5):1479-85 PubMed

Mycoses. 2005;48 Suppl 1:3-11 PubMed

J Reticuloendothel Soc. 1976 Feb;19(2):121-4 PubMed

Curr Mol Med. 2005 Jun;5(4):377-82 PubMed

Med Sci Monit. 2004 Aug;10(8):BR239-49 PubMed

Microbiology (Reading). 1999 Jul;145 ( Pt 7):1631-1640 PubMed

Infect Immun. 2000 Oct;68(10):5771-7 PubMed

J Infect Dis. 2001 Jan 15;183(2):277-285 PubMed

Med Mycol. 2002 Aug;40(4):359-75 PubMed

J Clin Microbiol. 1983 May;17(5):774-80 PubMed

Sex Transm Infect. 2004 Feb;80(1):48-53 PubMed

Infect Immun. 1996 Aug;64(8):3360-8 PubMed

Curr Mol Med. 2005 Jun;5(4):393-401 PubMed

J Exp Med. 1994 Feb 1;179(2):589-600 PubMed

Annu Rev Immunol. 2003;21:335-76 PubMed

Infect Immun. 1995 Nov;63(11):4506-14 PubMed

J Immunol. 2004 Mar 1;172(5):3059-69 PubMed

Infect Immun. 2004 May;72(5):2939-46 PubMed

Infect Immun. 1976 Jul;14(1):33-8 PubMed

Ceska Gynekol. 2005 Nov;70(6):453-9 PubMed

Blood. 1990 Oct 1;76(7):1405-9 PubMed

Microb Pathog. 2003 Feb;34(2):103-13 PubMed

Res Immunol. 1998 May-Jun;149(4-5):361-73; discussion 510-2 PubMed

Microbiol Immunol. 1977;21(12):703-25 PubMed

Eur J Immunol. 1993 May;23(5):1034-8 PubMed

Clin Infect Dis. 2003 Nov 1;37(9):1172-7 PubMed

Curr Mol Med. 2005 Jun;5(4):383-92 PubMed

Antimicrob Agents Chemother. 2000 Oct;44(10):2653-8 PubMed

Trends Microbiol. 2001 Jul;9(7):327-35 PubMed

J Dent Res. 2005 Nov;84(11):966-77 PubMed

Folia Microbiol (Praha). 2005;50(1):77-82 PubMed

Folia Microbiol (Praha). 2005;50(3):255-61 PubMed

Infect Immun. 2002 Dec;70(12):7081-8 PubMed

Infect Immun. 2002 May;70(5):2725-9 PubMed

Infect Control Hosp Epidemiol. 2005 Jun;26(6):540-7 PubMed

Infect Immun. 1995 Jul;63(7):2403-8 PubMed

Infect Immun. 2001 Nov;69(11):7162-4 PubMed

Trends Microbiol. 2002 Nov;10(11):508-14 PubMed

Genes Immun. 2005 Dec;6(8):672-82 PubMed

Br J Haematol. 2005 Jun;129(5):569-82 PubMed

Folia Microbiol (Praha). 2005;50(5):409-13 PubMed

Infect Immun. 1996 Sep;64(9):3793-9 PubMed

Folia Microbiol (Praha). 2002;47(2):179-81 PubMed

Folia Microbiol (Praha). 2002;47(3):302-4 PubMed

Clin Infect Dis. 2005 Nov 1;41(9):1232-9 PubMed

J Infect Dis. 2001 Dec 1;184(11):1489-93 PubMed

Infect Immun. 2000 Jul;68(7):3840-7 PubMed

Folia Microbiol (Praha). 2005;50(3):263-7 PubMed

Rev Assoc Med Bras (1992). 2003 Oct-Dec;49(4):434-8 PubMed

Infect Immun. 1995 Jul;63(7):2714-9 PubMed

Am J Reprod Immunol. 2001 Apr;45(4):200-4 PubMed

J Clin Microbiol. 1993 May;31(5):1354-7 PubMed

Chem Immunol. 1996;63:115-37 PubMed

Pediatr Infect Dis J. 2001 Feb;20(2):197-206 PubMed

J Infect Dis. 1992 Nov;166(5):1103-12 PubMed

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2005 Dec;149(2):243-9 PubMed

Med Mycol. 2000 Dec;38(6):419-31 PubMed

Science. 1994 Aug 26;265(5176):1237-40 PubMed

Curr Mol Med. 2005 Jun;5(4):443-52 PubMed

Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6688-92 PubMed

Infect Immun. 2002 Sep;70(9):4791-7 PubMed

Folia Microbiol (Praha). 2002;47(2):182-4 PubMed

Infect Immun. 1998 Dec;66(12):5771-6 PubMed

Infect Immun. 2002 Oct;70(10):5790-9 PubMed

Clin Infect Dis. 2003 Sep 1;37(5):634-43 PubMed

Infect Immun. 1997 Aug;65(8):3399-405 PubMed

Trends Immunol. 2004 Mar;25(3):150-7 PubMed

Mycopathologia. 1986 Nov;96(2):103-7 PubMed

Curr Mol Med. 2005 Jun;5(4):403-11 PubMed

Infect Immun. 2001 Aug;69(8):5072-9 PubMed

Curr Opin Infect Dis. 2005 Apr;18(2):107-11 PubMed

Oral Dis. 2002;8 Suppl 2:69-75 PubMed

J Cell Sci. 1999 Oct;112 ( Pt 19):3237-48 PubMed

New Microbiol. 2005 Oct;28(4):299-309 PubMed

Folia Microbiol (Praha). 1999;44(5):561-6 PubMed

Nat Biotechnol. 2000 Oct;18(10):1060-4 PubMed

J Exp Med. 1996 Apr 1;183(4):1345-55 PubMed

Infect Immun. 2002 Feb;70(2):724-31 PubMed

Clin Microbiol Rev. 1997 Oct;10(4):585-96 PubMed

J Immunol. 2000 Nov 1;165(9):5077-83 PubMed

Vaccine. 2004 Feb 17;22(7):865-71 PubMed

J Immunol. 1994 Apr 1;152(7):3514-21 PubMed

Curr Mol Med. 2002 Sep;2(6):507-24 PubMed

Clin Infect Dis. 2006 May 15;42(10):1404-13 PubMed

J Exp Med. 2005 Sep 5;202(5):597-606 PubMed

Molecular adjuvants based on nonpyrogenic lipophilic derivatives of norAbuMDP/GMDP formulated in nanoliposomes: stimulation of innate and adaptive immunity

Mutants of Candida albicans hypersensitive to calcofluor white display susceptibility to antifungal drugs